Instil Bio (TIL) has released an update.
Instil Bio, Inc. has agreed to partner with a collaborator to carry out preclinical manufacturing feasibility studies for its ITIL-306 program, aiming to progress to investigator-initiated clinical trials. The company has not offered any timeline for when data from these studies might become available.
For further insights into TIL stock, check out TipRanks’ Stock Analysis page.
